CN101812065B - 含有小于25ppm的14-羟可待因酮的盐酸羟可待酮 - Google Patents

含有小于25ppm的14-羟可待因酮的盐酸羟可待酮 Download PDF

Info

Publication number
CN101812065B
CN101812065B CN2010101515524A CN201010151552A CN101812065B CN 101812065 B CN101812065 B CN 101812065B CN 2010101515524 A CN2010101515524 A CN 2010101515524A CN 201010151552 A CN201010151552 A CN 201010151552A CN 101812065 B CN101812065 B CN 101812065B
Authority
CN
China
Prior art keywords
eudol eekodal
compsn
hydroxycodeinone
eudol
eekodal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CN2010101515524A
Other languages
English (en)
Chinese (zh)
Other versions
CN101812065A (zh
Inventor
罗伯特·查普曼
隆·S·里德
洪琦
唐纳德·凯尔
罗伯特·库佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101812065(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CN101812065A publication Critical patent/CN101812065A/zh
Application granted granted Critical
Publication of CN101812065B publication Critical patent/CN101812065B/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010101515524A 2004-03-30 2005-03-30 含有小于25ppm的14-羟可待因酮的盐酸羟可待酮 Ceased CN101812065B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60/557,492 2004-03-30
US60153404P 2004-08-13 2004-08-13
US60/601,534 2004-08-13
US62007204P 2004-10-18 2004-10-18
US60/620,072 2004-10-18
US64862505P 2005-01-31 2005-01-31
US60/648,625 2005-01-31
US65177805P 2005-02-10 2005-02-10
US60/651,778 2005-02-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2005800106471A Division CN1960994B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法

Publications (2)

Publication Number Publication Date
CN101812065A CN101812065A (zh) 2010-08-25
CN101812065B true CN101812065B (zh) 2012-03-28

Family

ID=35124996

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201210257643.5A Expired - Lifetime CN102838607B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法
CN2010101515524A Ceased CN101812065B (zh) 2004-03-30 2005-03-30 含有小于25ppm的14-羟可待因酮的盐酸羟可待酮
CN201210256799.1A Expired - Lifetime CN102887903B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法
CN2010106226501A Expired - Lifetime CN102127086B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法
CN2005800106471A Expired - Lifetime CN1960994B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201210257643.5A Expired - Lifetime CN102838607B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201210256799.1A Expired - Lifetime CN102887903B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法
CN2010106226501A Expired - Lifetime CN102127086B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法
CN2005800106471A Expired - Lifetime CN1960994B (zh) 2004-03-30 2005-03-30 制备含有小于25ppm的14-羟可待因酮的盐酸羟可待酮的方法

Country Status (38)

Country Link
US (35) US7129248B2 (enExample)
EP (7) EP2314589B1 (enExample)
JP (8) JP4912294B2 (enExample)
KR (12) KR20180088505A (enExample)
CN (5) CN102838607B (enExample)
AP (1) AP2232A (enExample)
AR (1) AR049012A1 (enExample)
AT (2) ATE501150T1 (enExample)
AU (2) AU2005230826C1 (enExample)
BR (1) BRPI0508758B8 (enExample)
CA (3) CA2913355C (enExample)
CR (2) CR8593A (enExample)
CY (5) CY1111487T1 (enExample)
DE (2) DE602005026786D1 (enExample)
DK (6) DK2319846T3 (enExample)
EA (1) EA013208B1 (enExample)
EC (1) ECSP066953A (enExample)
ES (6) ES2585576T3 (enExample)
FI (1) FI7843U1 (enExample)
HR (5) HRP20110425T4 (enExample)
HU (3) HUE028233T2 (enExample)
IL (8) IL178038A (enExample)
LT (2) LT2314589T (enExample)
MA (1) MA28492B1 (enExample)
ME (4) ME02482B (enExample)
MX (2) MX363228B (enExample)
MY (3) MY172063A (enExample)
NO (1) NO337669B1 (enExample)
NZ (3) NZ601326A (enExample)
PE (1) PE20050880A1 (enExample)
PL (5) PL2319846T3 (enExample)
PT (5) PT2305683E (enExample)
RS (5) RS54941B1 (enExample)
SG (3) SG10201406658VA (enExample)
SI (5) SI2305683T1 (enExample)
TW (3) TW201509943A (enExample)
WO (1) WO2005097801A1 (enExample)
ZA (1) ZA200607181B (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TW201509943A (zh) * 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT2112153E (pt) * 2005-03-04 2010-12-17 Euro Celtique Sa Método de diminuír a quantidade de cetonas insaturadas em alfa-beta em composições de opiáceos
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
EP1971607A2 (en) * 2005-11-22 2008-09-24 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
JP5695296B2 (ja) * 2006-03-02 2015-04-01 マリンクロッド エルエルシー 低レベルのアルファ，ベータ−不飽和ケトン化合物を伴うモルフィナン−６−オン生成物の製造方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008048711A1 (en) * 2006-10-17 2008-04-24 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
CA2671518C (en) * 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
AU2007329451B2 (en) * 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2681740A1 (en) * 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine
CA2684458A1 (en) 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
MX342643B (es) * 2008-09-18 2016-10-07 Purdue Pharma Lp Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
CA2765971C (en) * 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
ES2428938T3 (es) * 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
EP2473195A4 (en) * 2009-08-31 2013-01-16 Depomed Inc PHARMACEUTICAL MAGNETIC RELEASE COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHES
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
SE1251371A1 (sv) 2010-05-10 2012-12-27 Euro Celtique Sa Farmaceutiska kompositioner innefattande hydromorfon och naloxon
WO2011154826A1 (en) 2010-06-11 2011-12-15 Rhodes Technologies Process for n-dealkylation of tertiary amines
WO2011154827A2 (en) 2010-06-11 2011-12-15 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
ES2659168T3 (es) 2010-07-02 2018-03-14 Johnson Matthey Public Limited Company Proceso para la síntesis y purificación de oxicodona
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
PL2736495T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
ES2842453T3 (es) 2011-09-05 2021-07-14 Siegfried Ltd Kit que comprende un material de envasado y un producto farmacéutico o nutracéutico sólido contenido en el material de envasado
WO2013038268A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
US20140341984A1 (en) 2011-09-16 2014-11-20 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20150265536A1 (en) 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CN109820830A (zh) 2012-03-02 2019-05-31 罗德兹制药股份有限公司 抗破坏性立即释放型制剂类
DE112013002074T5 (de) 2012-04-17 2015-01-29 Purdue Pharma L.P. Systeme und Methoden zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
ES2638178T3 (es) 2012-07-16 2017-10-19 Rhodes Technologies Proceso para la síntesis mejorada de opioides
KR101946103B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
RS58427B1 (sr) 2012-08-03 2019-04-30 Johnson Matthey Plc Postupak za pripremu oksikodona
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
US9120800B2 (en) 2013-08-02 2015-09-01 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone alkaloid and oxymorphone salts
WO2015069717A1 (en) 2013-11-07 2015-05-14 Mallinckrodt Llc Production of 6-hydroxy morphinans without the isolation of intermediates
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
CA2937007C (en) 2014-01-15 2018-11-06 Rhodes Technologies Process for improved oxymorphone synthesis
US9932348B2 (en) 2014-01-15 2018-04-03 Rhodes Technologies Process for improved oxycodone synthesis
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
WO2016005923A1 (en) 2014-07-09 2016-01-14 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN110770238B (zh) * 2017-06-20 2022-10-04 庄信万丰股份有限公司 用于从14-羟可待因酮制备盐酸氧可酮的氢化方法
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262266B1 (en) * 1999-10-15 2001-07-17 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286431C (enExample)
DE296916C (enExample)
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US420098A (en) * 1890-01-28 Mowing-machine
US1468805A (en) 1923-09-25 Htabtin ereund
US1485673A (en) * 1924-03-04 Ministrator
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (enExample) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
KR930001499B1 (ko) * 1987-07-07 1993-03-02 오끼뎅끼 고오교오 가부시끼가이샤 반도체 장치의 제조방법
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
AU3508097A (en) 1996-06-26 1998-01-14 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
US6454970B1 (en) * 1998-10-14 2002-09-24 Amic Ab And Gyros Ab Matrix, method of producing and using the matrix and machine including the matrix
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
AU2001258825A1 (en) 2000-05-29 2001-12-11 Shionogi And Co., Ltd. Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
ATE506064T1 (de) * 2001-06-05 2011-05-15 Control Delivery Systems Analgetika mit verzögerter wirkstoffabgabe
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
ES2562682T3 (es) * 2002-01-15 2016-03-07 Novartis Ag Sistema para liberar aerosoles del espacio muerto anatómico efectivo
ES2327034T3 (es) * 2002-03-26 2009-10-23 Euro-Celtique S.A. Composiciones recubiertas con gel de liberacion sostenida.
NZ536252A (en) * 2002-04-29 2007-06-29 Alza Corp Methods and dosage forms for controlled delivery of oxycodone
EP1509050A4 (en) * 2002-05-27 2009-03-18 Ntt Docomo Inc MOBILE COMMUNICATION SYSTEM, TRANSMISSION STATION, RECEPTION STATION, RELAY STATION, METHOD FOR DECISION-MAKING THE COMMUNICATION PATH AND PROGRAM FOR DECISION-MAKING THE COMMUNICATION PATH
BR0304960A (pt) 2002-05-31 2005-01-04 Alza Corp Formas de dosagem e composições para liberação osmótica de dosagens variáveis de oxicodona
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
WO2004016618A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
AU2003291103A1 (en) 2002-11-15 2004-06-15 Branded Products For The Future Pharmaceutical composition
MXPA05005781A (es) * 2002-11-29 2005-12-12 Forest Laboratories Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
ATE454169T1 (de) 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TW201509943A (zh) * 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006004672A1 (en) 2004-06-25 2006-01-12 Tessera, Inc. Components with posts and pads
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
PT2112153E (pt) 2005-03-04 2010-12-17 Euro Celtique Sa Método de diminuír a quantidade de cetonas insaturadas em alfa-beta em composições de opiáceos
US8067597B2 (en) 2005-06-16 2011-11-29 Mallinckrodt Llc Synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs
EP1971607A2 (en) 2005-11-22 2008-09-24 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
JP5695296B2 (ja) 2006-03-02 2015-04-01 マリンクロッド エルエルシー 低レベルのアルファ，ベータ−不飽和ケトン化合物を伴うモルフィナン−６−オン生成物の製造方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
AU2007329451B2 (en) 2006-12-04 2012-08-30 Noramco, Llc Process for reducing impurities in oxycodone base
CA2671518C (en) * 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
ES2659168T3 (es) * 2010-07-02 2018-03-14 Johnson Matthey Public Limited Company Proceso para la síntesis y purificación de oxicodona
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262266B1 (en) * 1999-10-15 2001-07-17 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stacey J.Ackerman,et al..Patient-Reported Utilization Patterns of Fentanyl Transdermal System and Oxycodone Hydrochloride Controlled-Release Among Patients With Chronic Nonmalignant Pain.《Journal of Managed Care Pharmacy》.2003,第9卷(第3期), *

Also Published As

Publication number Publication date
EP2316837B1 (en) 2018-01-10
US9777011B2 (en) 2017-10-03
US9073933B2 (en) 2015-07-07
JP4912294B2 (ja) 2012-04-11
US20160264588A1 (en) 2016-09-15
NO337669B1 (no) 2016-05-30
US20100152449A1 (en) 2010-06-17
JP2015187134A (ja) 2015-10-29
EP2314589A1 (en) 2011-04-27
SI2319846T1 (sl) 2016-08-31
EA013208B1 (ru) 2010-04-30
JP2014139205A (ja) 2014-07-31
AP2006003738A0 (en) 2006-10-31
PL2316837T3 (pl) 2018-07-31
IL213888A0 (en) 2011-07-31
ME01299B (me) 2011-10-31
RS57000B1 (sr) 2018-05-31
ZA200607181B (en) 2007-11-28
US20160176888A1 (en) 2016-06-23
KR20200000499A (ko) 2020-01-02
RS53891B1 (sr) 2015-08-31
US20160251365A1 (en) 2016-09-01
IL213889A (en) 2012-06-28
PT2426132E (pt) 2016-03-31
RS54941B1 (sr) 2016-11-30
HRP20160885T1 (hr) 2016-09-23
EP1730151A4 (en) 2007-05-23
EP2319846B1 (en) 2016-05-04
TW201509943A (zh) 2015-03-16
EP2316837A1 (en) 2011-05-04
US20180022754A1 (en) 2018-01-25
PL2305683T3 (pl) 2015-07-31
KR101200700B1 (ko) 2012-11-13
DK2305683T3 (en) 2015-04-07
US20190161492A1 (en) 2019-05-30
CA2557845C (en) 2013-10-01
US20090227615A1 (en) 2009-09-10
PT2319846T (pt) 2016-08-12
IL178038A (en) 2015-10-29
PT1730151E (pt) 2011-06-01
US20070117829A1 (en) 2007-05-24
US20160185790A1 (en) 2016-06-30
US7129248B2 (en) 2006-10-31
EP2305683B2 (en) 2024-09-11
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
HRP20110425T1 (en) 2011-07-31
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
US10696684B2 (en) 2020-06-30
HRP20180407T1 (hr) 2018-04-20
CN1960994B (zh) 2012-09-05
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
PL2319846T3 (pl) 2016-12-30
DK1730151T3 (da) 2011-06-20
CY1117841T1 (el) 2017-05-17
JP5543991B2 (ja) 2014-07-09
CN102887903A (zh) 2013-01-23
HK1155728A1 (en) 2012-05-25
US20160175299A1 (en) 2016-06-23
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
PL2426132T3 (pl) 2016-06-30
SI2305683T1 (sl) 2015-04-30
CA2774121A1 (en) 2005-10-20
EP2311839A1 (en) 2011-04-20
EP2305683A1 (en) 2011-04-06
JP5118223B2 (ja) 2013-01-16
KR20100069719A (ko) 2010-06-24
IL241117A0 (en) 2015-11-30
US7683072B2 (en) 2010-03-23
CN1960994A (zh) 2007-05-09
IL214050A0 (en) 2011-08-31
EP2305683B8 (en) 2015-03-04
EP1730151B1 (en) 2011-03-09
US20230159548A1 (en) 2023-05-25
SG170735A1 (en) 2011-05-30
IL214050A (en) 2013-09-30
US20160176889A1 (en) 2016-06-23
HUE028233T2 (en) 2016-12-28
JP2012072162A (ja) 2012-04-12
US7674798B2 (en) 2010-03-09
TWI365880B (en) 2012-06-11
CY1116327T1 (el) 2017-02-08
SG10201406658VA (en) 2014-12-30
SI2316837T1 (en) 2018-05-31
MY172063A (en) 2019-11-13
AU2005230826C1 (en) 2014-10-16
DK200700214U3 (da) 2008-02-08
US20210198268A1 (en) 2021-07-01
PL1730151T5 (pl) 2023-09-18
LT2316837T (lt) 2018-04-10
HRP20160223T1 (hr) 2016-03-25
US20130005977A1 (en) 2013-01-03
IL178038A0 (en) 2006-12-31
HRP20110425T4 (hr) 2020-11-27
KR20130020962A (ko) 2013-03-04
CY1111487T1 (el) 2015-08-05
DE602005026786D1 (de) 2011-04-21
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
US20150265597A1 (en) 2015-09-24
US20200062772A1 (en) 2020-02-27
JP6503392B2 (ja) 2019-04-17
LT2314589T (lt) 2023-06-12
ME02411B (me) 2016-09-20
MX363228B (es) 2019-03-15
BRPI0508758B8 (pt) 2021-05-25
ES2535618T3 (es) 2015-05-13
IL213890A (en) 2015-10-29
CN102838607A (zh) 2012-12-26
JP5378486B2 (ja) 2013-12-25
IL213891A0 (en) 2011-07-31
US11384091B2 (en) 2022-07-12
AR049012A1 (es) 2006-06-21
ME03068B (me) 2019-01-20
AU2005230826B2 (en) 2008-11-06
JP2011157370A (ja) 2011-08-18
MY143205A (en) 2011-03-31
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
NO20064935L (no) 2006-12-18
SI1730151T2 (sl) 2021-03-31
CA2557845A1 (en) 2005-10-20
FIU20070284U0 (fi) 2007-07-04
US20150258086A1 (en) 2015-09-17
US20230365578A1 (en) 2023-11-16
DE202005021371U1 (de) 2007-10-25
PT2316837T (pt) 2018-04-02
EP2305683B1 (en) 2015-01-28
US10259819B2 (en) 2019-04-16
US20160251363A1 (en) 2016-09-01
JP2017125052A (ja) 2017-07-20
US20160175298A1 (en) 2016-06-23
DK1730151T4 (da) 2020-10-19
PE20050880A1 (es) 2005-11-16
CR20110376A (es) 2011-09-19
CA2913355C (en) 2021-04-20
BRPI0508758B1 (pt) 2018-10-09
KR20120046309A (ko) 2012-05-09
US20150265598A1 (en) 2015-09-24
FI7843U1 (fi) 2008-04-28
US20210094963A1 (en) 2021-04-01
EP2426132B1 (en) 2016-01-13
HK1098745A1 (en) 2007-07-27
EP1730151A1 (en) 2006-12-13
AU2005230826A1 (en) 2005-10-20
NZ601326A (en) 2013-10-25
US8822687B2 (en) 2014-09-02
KR20110110377A (ko) 2011-10-06
ATE501150T1 (de) 2011-03-15
KR20070022033A (ko) 2007-02-23
JP2018184462A (ja) 2018-11-22
CY1120171T1 (el) 2018-12-12
CN102887903B (zh) 2016-01-27
US7674800B2 (en) 2010-03-09
EP1730151B2 (en) 2020-09-16
IL213890A0 (en) 2011-07-31
NZ549430A (en) 2010-05-28
JP2007531756A (ja) 2007-11-08
TW201231469A (en) 2012-08-01
MX2020008878A (es) 2020-11-09
CR8593A (es) 2007-07-19
KR101410141B1 (ko) 2014-06-25
TWI483944B (zh) 2015-05-11
US20160185789A1 (en) 2016-06-30
US20160251364A1 (en) 2016-09-01
DK200700214U1 (da) 2007-11-23
ES2585576T3 (es) 2016-10-06
ES2938727T3 (es) 2023-04-14
MA28492B1 (fr) 2007-03-01
ME02482B (me) 2017-02-20
EP2319846A1 (en) 2011-05-11
KR20090104145A (ko) 2009-10-05
US20050222188A1 (en) 2005-10-06
US7674799B2 (en) 2010-03-09
US12060361B2 (en) 2024-08-13
CA2774121C (en) 2016-02-16
DK2319846T3 (en) 2016-08-15
HK1155729A1 (en) 2012-05-25
CN102838607B (zh) 2016-08-03
EP2426132A1 (en) 2012-03-07
KR20140021716A (ko) 2014-02-20
US10407434B2 (en) 2019-09-10
ES2362282T5 (es) 2021-06-24
JP2012188439A (ja) 2012-10-04
ES2362282T3 (es) 2011-06-30
DK2426132T3 (en) 2016-04-04
WO2005097801A1 (en) 2005-10-20
AT9952U1 (de) 2008-06-15
BRPI0508758A (pt) 2007-08-28
US20200087316A1 (en) 2020-03-19
SI1730151T1 (sl) 2011-06-30
CN101812065A (zh) 2010-08-25
RS51693B2 (sr) 2021-02-26
CA2913355A1 (en) 2005-10-20
US20160185788A1 (en) 2016-06-30
PL1730151T3 (pl) 2011-08-31
US9522919B2 (en) 2016-12-20
KR20180088505A (ko) 2018-08-03
US20070117831A1 (en) 2007-05-24
SG170736A1 (en) 2011-05-30
DK2316837T3 (en) 2018-04-16
KR20120106784A (ko) 2012-09-26
CN102127086A (zh) 2011-07-20
PT2305683E (pt) 2015-05-18
EP2314589B1 (en) 2022-12-28
KR20140133615A (ko) 2014-11-19
US20060173029A1 (en) 2006-08-03
HUE036451T2 (hu) 2018-07-30
US20070179169A1 (en) 2007-08-02
IL241117B (en) 2020-06-30
MY154985A (en) 2015-08-28
ES2665287T3 (es) 2018-04-25
AU2009200335B2 (en) 2011-07-28
RS54598B1 (sr) 2016-08-31
SI2426132T1 (sl) 2016-04-29
IL213889A0 (en) 2011-07-31
RS51693B (sr) 2011-10-31
AU2009200335A1 (en) 2009-02-26
US20160250204A1 (en) 2016-09-01
IL235298A (en) 2016-11-30
EA200601520A1 (ru) 2007-02-27
US10689389B2 (en) 2020-06-23
ECSP066953A (es) 2006-12-20
CY1117228T1 (el) 2017-04-05
HUE029913T2 (en) 2017-04-28

Similar Documents

Publication Publication Date Title
CN101812065B (zh) 含有小于25ppm的14-羟可待因酮的盐酸羟可待酮
AU2017204741B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
AU2013202453B2 (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
HK1149560A (en) Oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone
HK1156303A (en) Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
HK1149561A (en) Process for preparing oxycodone hydrochloride having less than 25ppm 14-hydroxycodeinone
HK1098745B (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220129

Address after: Connecticut, USA

Patentee after: PURDUE PHARMA L.P.

Address before: Luxemburg Luxemburg City

Patentee before: EURO-CELTIQUE S.A.

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20220531

Decision number of declaring invalidation: 56163

Granted publication date: 20120328